What's the time limit for yervoy's offer?

How Long Does the Yervoy Offer Remain in Effect?

Yervoy (ipilimumab) is an immunotherapy medication used to treat various types of cancer, including melanoma [1]. The availability and pricing of Yervoy can be affected by patent exclusivity, which grants the manufacturer a certain timeframe to be the sole producer of the medication.

When Does Exclusivity Expire?

According to DrugPatentWatch.com, the patent for Yervoy expires in [2026] [2]. However, it is essential to note that patent expiration does not necessarily mean that the medication will immediately become available as a generic or biosimilar. The manufacturer may continue to produce and market the medication under brand-name Yervoy, and generic or biosimilar versions may enter the market at a later date.

What Happens After Exclusivity Expire?

After the patent expires, other manufacturers may apply to the FDA for approval to market generic or biosimilar versions of Yervoy. However, this process can take several years, and the exact timeline depends on various factors, including the FDA's review process and any potential litigation [3].

Can Biosimilars Enter Before Patent Expiration?

In some cases, biosimilar manufacturers may apply for FDA approval before the patent expires. This is possible if the manufacturer can demonstrate that their product is sufficiently different from the original medication to avoid patent infringement [4].

References:

[1] FDA. (2011). Yervoy (ipilimumab) label.

[2] DrugPatentWatch.com. (2023). Yervoy (ipilimumab) patent expiration.

[3] FDA. (2022). Biosimilars: Questions and Answers.

[4] Biotech Innovation Organization. (2022). Biosimilars: A Guide for Patients.